Breakdown | ||||
Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 |
---|---|---|---|---|
Income Statement | Total Revenue | |||
1.36M | 50.90K | 78.13K | 7.85M | 443.55K | Gross Profit |
937.48K | -505.24K | -558.01K | 7.06M | 87.74K | EBIT |
0.00 | -767.60K | -1.20M | 5.27M | -390.42K | EBITDA |
-811.88K | -788.22K | -695.49K | 5.28M | -371.80K | Net Income Common Stockholders |
-7.25M | 1.58M | 1.45M | 13.94M | -575.53K |
Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | |||
1.74M | 934.86K | 1.89M | 2.14M | 684.89K | Total Assets |
3.50M | 11.61M | 7.06M | 3.20M | 2.08M | Total Debt |
0.00 | 0.00 | 0.00 | 13.18K | 22.02K | Net Debt |
-1.74M | -934.86K | -1.89M | -2.13M | -662.88K | Total Liabilities |
104.14K | 1.09M | 449.86K | 632.92K | 302.70K | Stockholders Equity |
3.40M | 10.52M | 6.63M | 2.57M | 1.70M |
Cash Flow | Free Cash Flow | |||
-736.12K | -768.19K | -1.28M | -1.29M | -369.20K | Operating Cash Flow |
-736.12K | -768.19K | -1.27M | -1.28M | -352.20K | Investing Cash Flow |
1.54M | -1.08M | -1.40M | 17.09M | -34.78K | Financing Cash Flow |
0.00 | 930.36K | 2.42M | -14.35M | -135.41K |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
---|---|---|---|---|---|---|---|
74 Outperform | 22.12 | 3.22% | 7.33% | -3.67% | 51.49% | ||
72 Outperform | 7.34 | 12.49% | 0.45% | ― | ― | ||
70 Outperform | 4.43 | 21.58% | ― | 52.96% | 30.01% | ||
64 Neutral | $14.25B | 10.26 | 8.97% | 4.33% | 16.33% | -11.91% | |
54 Neutral | £508.15M | ― | -0.51% | ― | 59.93% | 97.07% | |
50 Neutral | £3.19M | ― | -97.45% | ― | 502.47% | -501.58% |
Braveheart Investment Group plc has increased its stake in IQ-AI Ltd by subscribing to 7,000,000 new shares in a recent placing, raising its holding to 29.35% of IQ-AI’s enlarged share capital. This strategic investment is seen as a significant addition to Braveheart’s portfolio, potentially enhancing its market position and offering stakeholders increased value through IQ-AI’s innovative imaging platforms and therapeutics.
Braveheart Investment Group plc has announced the cancellation of a substantial number of share options previously granted to its CEO, Trevor Brown, and Executive Director, Vivian Hallam, as part of a long-term incentive plan. The cancellation involves 2,976,192 options and follows a series of option grants and cancellations dating back to 2020. This strategic move reduces the total outstanding options to 7,146,000 ordinary shares, which now represent 11.21% of the company’s issued share capital, potentially affecting the company’s future share distribution and stakeholders’ interests.
Braveheart Investment Group plc has announced a significant increase in the shareholding of its Chief Executive Officer, Trevor Brown. On 20 January 2025, Brown purchased 250,000 ordinary shares at 5.5 pence each, raising his total beneficial shareholding to approximately 26.04% of the company’s voting rights. This move underscores Brown’s confidence in the company’s future prospects and could potentially influence investor perceptions positively, reflecting a strong commitment from the leadership towards Braveheart’s strategic goals.
Braveheart Investment Group plc announced the appointment of MAH, Chartered Accountants, as their new auditor, replacing PKF Littlejohn LLP. This change is set to impact the auditing of the company’s financial statements for the year ending March 2025, pending shareholder approval at the upcoming Annual General Meeting.